US 11,834,443 B2
Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
Cyrille Lescop, Allschwil (CH); Jasper Dingemanse, Allschwil (CH); and Andreas Krause, Allschwil (CH)
Assigned to Idorsia Pharmaceuticals Ltd, Allschwil (CH)
Filed by Idorsia Pharmaceuticals Ltd, Allschwil (CH)
Filed on Jul. 1, 2022, as Appl. No. 17/810,545.
Application 17/810,545 is a continuation of application No. 17/070,876, filed on Oct. 14, 2020, granted, now 11,390,615.
Application 17/070,876 is a continuation of application No. 16/503,245, filed on Jul. 3, 2019, granted, now 10,836,754, issued on Nov. 17, 2020.
Application 16/503,245 is a continuation of application No. 15/575,332, granted, now 10,385,043, issued on Aug. 20, 2019, previously published as PCT/EP2016/061200, filed on May 19, 2016.
Claims priority of application No. PCT/EP2015/061153 (WO), filed on May 20, 2015.
Prior Publication US 2023/0002365 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/04 (2006.01); A61P 37/00 (2006.01); A61K 31/047 (2006.01); A61K 31/4245 (2006.01); A61K 31/44 (2006.01); G01N 23/20 (2018.01)
CPC C07D 413/04 (2013.01) [A61K 31/047 (2013.01); A61K 31/4245 (2013.01); A61K 31/44 (2013.01); A61P 37/00 (2018.01); G01N 23/20075 (2013.01)] 26 Claims
 
1. A pharmaceutical composition comprising a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol and a pharmaceutically acceptable carrier, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 5.4°, 8.5°, and 10.8°; and wherein the pharmaceutical composition comprises about 2 mg or about 4 mg of the compound.